New Tools Enable Large-Scale Studies of Gene Function
News Apr 10, 2006
A molecular library created by a research team led by scientists at the Broad Institute of MIT and Harvard has promised to accelerate scientists' understanding of the genetics behind cancer and many biological processes.
In the March 24 issue of Cell, the team, working through the RNAi Consortium (TRC), announced the construction and worldwide availability of a library of molecular reagents that silence most human and mouse genes.
The library consists of small RNA molecules, known as RNA-interference inhibitors that can switch off genes individually. That capability will allow scientists to dissect the genetic underpinnings of normal biology and disease.
"Switching off a single gene through RNAi reveals how that gene functions in a particular biological process. When RNAi's potential is applied to thousands of genes - as it has been in fruit flies and nematodes - it can provide a more complete picture of that process," said David Root, director of the RNAi platform at the Broad Institute and director of TRC.
"Thanks to this unique public-private effort, we now have new tools to enable the entire research community to realize the potential of RNAi in the two most important species in biomedicine," said Root, a senior author of the Cell paper.
RNAi gives scientists the ability to turn off an individual gene. Each of the small RNA molecules is tailored to match a fragment of a gene's unique DNA, to which it binds, rendering the gene inactive.
The parallel analysis of thousands of genes using RNAi allows researchers to readily pinpoint the genes that control a biological process. TRC researchers developed techniques and quality-control measures that make it possible to perform such large-scale analysis.
"The RNAi library developed by the RNAi Consortium is a rich resource for biological discovery," said Nir Hacohen, assistant professor at Massachusetts General Hospital and Harvard Medical School, associate member of the Broad Institute and a senior author.
"Ongoing studies in my own laboratory to understand how the immune system senses pathogens and appropriately targets its response will be accelerated using these tools."
To evaluate the RNAi library's performance, the scientists sampled a subset that targets approximately 1,000 human genes. They systematically inactivated these genes in a human cancer cell line to identify the genes that regulate cell division during malignancy.
Automated cellular imaging was used to efficiently identify dividing cells in thousands of samples. This approach uncovered 100 previously unknown growth regulators, in addition to several known players, confirming the library's sensitivity as a vehicle for gene discovery.
"This critical new tool illustrates the requirement for academic and industry partnerships to drive scientific innovation," said Eric Lander, director of the Broad Institute, a member of the Whitehead Institute for Biomedical Research, an MIT professor of biology, and a senior author on the Cell paper.
"The importance of putting these reagents in the public domain will be demonstrated by the many important biomedical discoveries that will stem from them."
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
CRISPR Editing Stops HIV Virus in Infected CellsNews
Human immunodeficiency virus-1 (HIV-1) infection is a chronic disease affecting more than 35 million people worldwide. The infection can be controlled by antiretroviral therapy (ART), but there is still no complete cure. Now, a new study targeting the regulatory genes of the virus using CRISPR/Cas9 has helped block the production of the virus by infected cells.READ MORE